XML 45 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Strategic License and Research and Collaboration Agreements - Additional Information (Details)
£ in Millions
 1 Months Ended 3 Months Ended
Jan. 31, 2025
USD ($)
May 31, 2024
USD ($)
Mar. 31, 2024
USD ($)
Oct. 31, 2023
USD ($)
Feb. 28, 2022
USD ($)
Nov. 30, 2015
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2025
GBP (£)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research and development expenses             $ 52,151,000   $ 45,757,000  
Fund received upon completion of certain development milestone $ 1,500,000                  
2015 TSRI License Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Milestones achieved             0      
Milestone Payments       $ 300,000            
Accrued Royalties             $ 0      
2015 TSRI License Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Development and regulatory milestone payments           $ 1,500,000        
Commercial milestone payments           $ 3,500,000        
Amgen Research and Collaboration Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration agreement termination description             The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024. The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024.    
Research and collaboration agreement quarterly payments for first two year             $ 50,000,000      
Related party transaction obligation with related party             6,300,000     $ 0
Research and development expenses             6,300,000   0  
Amgen Research and Collaboration Agreement | Minimum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research and collaboration agreement quarterly payments for third year             $ 12,500,000      
Vanderbilt Research Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research agreement expiry date             2023-09 2023-09    
First Vanderbilt Research Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research and collaboration agreement quarterly payments         $ 1,700,000          
Second Vanderbilt Research Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research agreement expiry date             2025-03 2025-03    
Second Vanderbilt Research Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research and collaboration agreement payments   $ 600,000                
Parkinson's Research Ventures Funding Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research and development expenses             $ 200,000   $ 200,000  
Payments for execution of agreement     $ 1,100,000              
Maximum repayment amount agreed to pay. | £               £ 8.4    
Parkinson's Research Ventures Funding Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Funds provided for preclinical research and development activities             $ 2,600,000